Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Keros Therapeutics (NASDAQ:KROS) posted its quarterly earnings data on Wednesday. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13), Briefing.com reports. The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The business’s revenue was up 4750.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.33) earnings per share.

Keros Therapeutics Trading Up 1.0 %

Shares of NASDAQ KROS traded up $0.69 during midday trading on Thursday, reaching $67.14. The company’s stock had a trading volume of 280,507 shares, compared to its average volume of 368,850. The company has a 50 day moving average price of $57.30 and a 200 day moving average price of $51.99. Keros Therapeutics has a one year low of $27.31 and a one year high of $73.00. The company has a market cap of $2.52 billion, a price-to-earnings ratio of -13.09 and a beta of 1.23.

Insider Activity

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the transaction, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KROS. Guggenheim began coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target on the stock. Bank of America reduced their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Cantor Fitzgerald assumed coverage on shares of Keros Therapeutics in a research report on Thursday, October 24th. They set an “overweight” rating for the company. Scotiabank started coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. Finally, Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research report on Tuesday. They set a “buy” rating on the stock. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Keros Therapeutics has a consensus rating of “Buy” and a consensus price target of $88.89.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.